SK Biopharmaceuticals Co., Ltd. (KRX:326030)
South Korea · Delayed Price · Currency is KRW 79,400
-4,000 (-4.80%)
Sep 11, 2026, 3:30 PM KST
SK Biopharmaceuticals Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, SK Biopharmaceuticals stock has a consensus rating of "Buy" and an average price target of ₩130,333. The average 1-year stock price forecast is 64.15% higher than the current stock price, while the lowest is ₩74,000 (-6.80%) and the highest is ₩160,000 (+101.51%).
Price Target: ₩130,333 (+64.15%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for SK Biopharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 7 | 7 | 5 | 5 | 5 |
| Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 14 | 13 | 13 | 11 | 12 | 12 |
Financial Forecast
Revenue This Year
977.82B
from 706.74B
Increased by 38.36%
Revenue Next Year
1.16T
from 977.82B
Increased by 18.86%
EPS This Year
4.22K
from 3.41K
Increased by 23.87%
EPS Next Year
5.23K
from 4.22K
Increased by 23.88%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is KRW.